Why BrainsWay Ltd.’s (BWAY) Stock Is Up 5.67%
As of Tuesday, October 13, BrainsWay Ltd.’s BWAY share price has surged by 5.67%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Commentary & Analysis
Is BrainsWay Ltd. (BWAY) Overvalued?
We dive into why BrainsWay Ltd. (BWAY) could be considered overvalued on 2026-09-30, based on AAII’s Value Score and Grade.Michael Rose
Why BrainsWay Ltd.’s (BWAY) Stock Is Down 6.57%
As of Monday, July 13, BrainsWay Ltd.’s BWAY share price has dipped by 6.57%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why BrainsWay Ltd.’s (BWAY) Stock Is Down 5.24%
As of Tuesday, July 07, BrainsWay Ltd.’s BWAY share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why BrainsWay Ltd.’s (BWAY) Stock Is Up 5.13%
As of Monday, July 06, BrainsWay Ltd.’s BWAY share price has surged by 5.13%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | BWAY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $473.3 | $376.8 | 37% |
|
| Shares Out (Mil) | 38.7 | 40.7 | 42% |
|
| Institutional Ownership | 69.1% | 83.2% | 43% |
|
| Float (Mil) | 24.1 | 35.1 | 32% |
|
| Beta | 0.08 | 0.85 | 8% |
|
| Avg Daily Volume (000s) | 134 | 314 | 39% |
|
| Price Change (52-week) |
51.9% | 61.6% | 86% |
|
| Growth | BWAY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 18.8% | 11.8% | 79% |
|
| Net Income (5yr) | 27.8% | (5.5%) | 83% |
|
| EPS (5yr) | 22.5% | 10.4% | 72 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 28.2% | (15.5%) | 85% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.087 | $0.307 | $0.507 | |
| Month Ago EPS | $0.087 | $0.307 | $0.507 | |
| # Rev Up | 2 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | $0.095 | $0.330 | $0.540 | |
| Year/Year Chg | 27.9% | 68.7% | 196.7% | |
| Financials | BWAY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $61 | $128 | 22% |
|
| Net Income (TTM) (Mil) | $9 | ($9) | 45% |
|
| EPS (TTM) | $0.243 | ($0.400) | 48% |
|
| Operating Cash Flow (TTM) (Mil) | $8 | ($2) | 37% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $1 | 41% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $26 | 25% |
|
| Enterprise Value (Q1) (Mil) | $476 | $409 | 33% |
|
| Valuation | BWAY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.84 | 2.49 | 83% |
|
| P/E | 50.3 | 25.3 | 85% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 2.2 | 1.5 | 72% |
|
| Ratios | BWAY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.3% | 59.0% | 85% |
|
| Net Margin | 15.6% | (6.9%) | 73% |
|
| ROA | 8.7% | (12.2%) | 84% |
|
| ROE | 13.3% | (10.7%) | 67% |
|
| Liabilities to Assets | 35.1% | 47.2% | 26% |
|
| F-Score | 5 | 4 | 50% |
|
BrainsWay Ltd. did not pass any screens on 10/14/2026.
